NSNicole Schneider‐Daum

Nicole Schneider‐Daum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicole Schneider‐Daum has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Front Cover: pH‐Responsive Isoprenoid‐Antitumoral Polymer Conjugates for Superior Drug Loading via Self‐Assembly and Endosomal‐Targeted Anticancer Activity (ChemMedChem 5/2026)

    by Camilla Passi, Tobias Neu, Nicole Schneider‐Daum, Claus‐Michael Lehr, Marc Schneider, Sangeun Lee

  • Open Access

    pH‐Responsive Isoprenoid‐Antitumoral Polymer Conjugates for Superior Drug Loading via Self‐Assembly and Endosomal‐Targeted Anticancer Activity

    by Camilla Passi, Tobias Neu, Nicole Schneider‐Daum, Claus‐Michael Lehr, Marc Schneider, Sangeun Lee

    Polymer‐drug conjugates (PDCs) are a promising strategy to enhance the delivery of poorly soluble drugs, particularly in cancer therapy. By improving solubility and enabling site‐specific accumulation, PDCs minimize systemic toxicity while maximizing therapeutic efficacy. PDCs often employ stimuli‐responsive linkers, such as Schiff's bases, to achieve controlled drug release in tumor microenvironments or acidic intracellular compartments. In this study, we designed a novel PDC by conjugating the anticancer agent farnesal (Far) to ∈‐Poly‐L‐Lysine (PL) via an imine bond, without using additional linkers. PL is a natural, biodegradable, water‐soluble polymer with inherent anticancer properties, while Far is a hydrophobic isoprenoid with potent antitumor activity. The conjugate (Far‐PL) displayed pH‐responsive behavior, remaining stable at physiological pH but releasing drugs under acidic tumor (pH 6.5) and endosomal (pH 5.5) conditions. Far‐PL exhibited enhanced cytotoxicity against A549 lung cancer cells compared to its components alone, while showing reduced toxicity towards noncancerous cells (Arlo cells). The amphiphilicity allows the conjugate to self‐assemble into stable nanoparticles with a positive surface charge, narrow size distribution, and 100% drug content—clearly exceeding conventional nanoparticles (5–10 wt%). This effective PDC design demonstrates strong potential to maximize tumor‐selective activity while minimizing off‐target effects, offering a promising platform for future cancer therapeutics.


  • Open Access

    A stretchable human lung‐on‐chip model of alveolar inflammation for evaluating anti‐inflammatory drug response

    by Clémentine Richter, Lorenz Latta, Daria Harig, Patrick Carius, Janick D. Stucki, Nina Hobi, Andreas Hugi, Paul Schumacher, Tobias Krebs, Alexander Gamrekeli, et al.

    This study describes a complex human in vitro model for evaluating anti‐inflammatory drug response in the alveoli that may contribute to the reduction of animal testing in the pre‐clinical stage of drug development. The model is based on the human alveolar epithelial cell line Arlo co‐cultured with macrophages differentiated from the THP‐1 cell line, creating a physiological biological microenvironment. To mimic the three‐dimensional architecture and dynamic expansion and relaxation of the air‐blood‐barrier, they are grown on a stretchable microphysiological lung‐on‐chip. For validating the in vitro model, three different protocols have been developed to demonstrate the clinically established anti‐inflammatory effect of glucocorticoids to reduce certain inflammatory markers after different pro‐inflammatory stimuli: (1) an inflammation caused by bacterial LPS (lipopolysaccharides) to simulate an LPS‐induced acute lung injury measured best with cytokine IL‐6 release; (2) an inflammation caused by LPS at ALI (air‐liquid interface) to investigate aerosolized anti‐inflammatory treatment, measured with chemokine IL‐8 release; and (3) an inflammation with a combination of human inflammatory cytokines TNFα and IFNγ to simulate a critical cytokine storm leading to epithelial barrier disruption, where the eventual weakening or protection of the epithelial barrier can be measured. In all cases, the presence of macrophages appeared to be crucial to mediating inflammatory changes in the alveolar epithelium. LPS induction led to inflammatory changes independently of stretch conditions. Dynamic stretch, emulating breathing‐like mechanics, was essential for in vitro modeling of the clinically relevant outcome of epithelial barrier disruption upon TNFα/IFNγ‐induced inflammation.


  • Open Access

    A Monoclonal Human Alveolar Epithelial Cell Line (“Arlo”) with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections

    by Patrick Carius, Annemarie Jungmann, Marco Bechtel, Alexander Grißmer, Annette Boese, Gilles Gasparoni, Abdulrahman Salhab, Ralf Seipelt, Klaus Urbschat, Clémentine Richter, et al.

    In the development of orally inhaled drug products preclinical animal models regularly fail to predict pharmacological as well as toxicological responses in humans. Models based on human cells and tissues are potential alternatives to animal experimentation allowing for the isolation of essential processes of human biology and making them accessible in vitro. Here, the generation of a novel monoclonal cell line “Arlo,” derived from the polyclonal human alveolar epithelium lentivirus immortalized cell line hAELVi via single‐cell printing, and its characterization as a model for the human alveolar epithelium as well as a building block for future complex in vitro models is described. “Arlo” is systematically compared in vitro to primary human alveolar epithelial cells (hAEpCs) as well as to the polyclonal hAELVi cell line. “Arlo” cells show enhanced barrier properties with high transepithelial electrical resistance (TEER) of ≈3000 Ω cm2 and a potential difference (PD) of ≈30 mV under air–liquid interface (ALI) conditions, that can be modulated. The cells grow in a polarized monolayer and express genes relevant to barrier integrity as well as homeostasis as is observed in hAEpCs. Successful productive infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in a proof‐of‐principle study offers an additional, attractive application of “Arlo” beyond biopharmaceutical experimentation.


  • Open Access

    An Outer Membrane Vesicle‐Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability

    by Robert Richter, Mohamed A. M. Kamal, Marcus Koch, Bart‐Jan Niebuur, Anna‐Lena Huber, Adriely Goes, Carsten Volz, Julia Vergalli, Tobias Kraus, Rolf Müller, et al.

    When searching for new antibiotics against Gram‐negative bacterial infections, a better understanding of the permeability across the cell envelope and tools to discriminate high from low bacterial bioavailability compounds are urgently needed. Inspired by the phospholipid vesicle‐based permeation assay (PVPA), which is designed to predict non‐facilitated permeation across phospholipid membranes, outer membrane vesicles (OMVs) of Escherichia coli either enriched or deficient of porins are employed to coat filter supports for predicting drug uptake across the complex cell envelope. OMVs and the obtained in vitro model are structurally and functionally characterized using cryo‐TEM, SEM, CLSM, SAXS, and light scattering techniques. In vitro permeability, obtained from the membrane model for a set of nine antibiotics, correlates with reported in bacterio accumulation data and allows to discriminate high from low accumulating antibiotics. In contrast, the correlation of the same data set generated by liposome‐based comparator membranes is poor. This better correlation of the OMV‐derived membranes points to the importance of hydrophilic membrane components, such as lipopolysaccharides and porins, since those features are lacking in liposomal comparator membranes. This approach can offer in the future a high throughput screening tool with high predictive capacity or can help to identify compound‐ and bacteria‐specific passive uptake pathways.


  • Open Access

    Modulating the Barrier Function of Human Alveolar Epithelial (hAELVi) Cell Monolayers as a Model of Inflammation

    by Julia Katharina Metz, Birgit Wiegand, Sabrina Schnur, Katharina Knoth, Nicole Schneider-Daum, Henrik Groß, Glenn Croston, Torsten Michael Reinheimer, Claus-Michael Lehr, Marius Hittinger

    The incidence of inflammatory lung diseases such as acute respiratory distress syndrome (ARDS) remains an important problem, particularly in the present time with the Covid-19 pandemic. However, an adequate in vitro test system to monitor the barrier function of the alveolar epithelium during inflammation and for assessing anti-inflammatory drugs is urgently needed. Therefore, we treated human Alveolar Epithelial Lentivirus-immortalised cells (hAELVi cells) with the pro-inflammatory cytokines TNF-α (25 ng/ml) and IFN-γ (30 ng/ml), in the presence or absence of hydrocortisone (HC). While TNF-α and IFN-γ are known to reduce epithelial barrier properties, HC could be expected to protect the barrier function and result in an anti-inflammatory effect. We investigated the impact of anti-inflammatory/inflammatory treatment on transepithelial electrical resistance (TEER) and the apparent permeability coefficient (P app ) of the low permeability marker sodium fluorescein (NaFlu). After incubating hAELVi cells for 48 hours with a combination of TNF-α and IFN-γ, there was a significant decrease in TEER and a significant increase in the P app . The presence of HC maintained the TEER values and barrier properties, so that no significant P app change was observed. By using hAELVi cells to study anti-inflammatory drugs in vitro, the need for animal experiments could be reduced and pulmonary drug development accelerated.